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Protein kinases are important regulators of almost every
cellular function in eukaryotes. They catalyze the transfer of
a phosphate group onto serine, threonine or tyrosine amino
acid residues, resulting in a change of activity of the
substrate protein. The identification of the physiological
substrates of a kinase constitutes an important but
intimidating challenge for many biologists. A recent paper
by Jennifer Snead and colleagues in Chemistry and Biology
[1] reports the development of a multidisciplinary approach
to the identification of protein kinase substrates that has led
to the discovery of a novel mitotic role for the Polo-like
kinase in the budding yeast Saccharomyces cerevisiae
(where it is called Cdc5), implicating novel molecular
substrates.
Progression and regulation of the cell-division cycle relies
strongly on kinases, including the cyclin-dependent kinases
(Cdks), Aurora kinases and Polo-like kinases [2]. Each of
these families has been conserved in eukaryotes, from yeasts
to humans. Originally discovered in Drosophila [3], Polo-
like kinases are known to promote and coordinate several
events of mitosis and cytokinesis in a multitude of models
[4,5]. Among their most crucial functions, Polo-like kinases
promote centrosome maturation and separation (in animal
cells), sister-chromatid separation in prophase, activation of
the equally important Cdks, establishment of a bipolar
spindle and cytokinesis. To facilitate their targeting to the
appropriate subcellular locations, Polo-like kinases possess a
carboxy-terminal Polo-box domain (PBD), which enables
these enzymes to dock to proteins that have been pre-
phosphorylated (primed) at a specific motif by Polo-like
kinases themselves or by other kinases. Humans have four
Polo-like kinases (Plk1-4). Plk1-3 are most closely related to
Drosophila Polo and these have partially diverging
functions, with Plk1 fulfilling most of the functions in cell
division. Plk4 has a separate function in centriole duplica-
tion in humans and flies. The yeasts have single Plks: Cdc5
in budding yeast and Plo1 in fission yeast. Plk1 is often de-
regulated in many cancers, which has stimulated the
development of several chemical inhibitors with therapeutic
potential [6-8]. Nevertheless, surprisingly few phosphory-
lation substrates of the Polo kinases are known, and it is
suspected that many more remain to be identified before we
have a full picture of how these kinases impact on cell
division at the molecular level.
E Ex xi is st ti in ng g   a ap pp pr ro oa ac ch he es s   f fo or r   i id de en nt ti if fy yi in ng g   k ki in na as se e   s su ub bs st tr ra at te es s
Searching the protein sequence complement for particular
sequences can often aid the identification of kinase sub-
strates. Kinases differ in substrate specificity, preferring
different sequence motifs around the residue to be phos-
phorylated. For some of the better-characterized kinases,
their substrate-motif preference is known, making it
possible to predict whether a given protein is likely to be
phosphorylated. The primary sequence of a potential
sequence does not, however, allow prediction with high
confidence of whether a particular segment of the protein
will be accessible to phosophorylation by a kinase (for
example, it may be buried in the protein core or sterically
hindered by an interacting protein). Moreover, kinase and
substrates need to meet in space and time in the cell for thereaction to occur. For these reasons, genomic analysis alone
has a very limited capacity to identify physiological sub-
strates of protein kinases.
Various strategies have been used to attempt the systematic
identification of kinase substrates experimentally. In vitro
screens exploiting the change in electrophoretic mobility of
proteins after phosphorylation have been carried out, starting
with pools of radiolabeled proteins transcribed and
translated  in vitro, with some success [9,10]. Substrates
identified in such in vitro reactions must, however, then be
validated in vivo. Another approach is to purify the kinase by
affinity-based methods and identify co-purifying proteins
using mass spectrometry [11]. Proteins co-purifying with a
kinase are often physiological phosphorylation substrates,
but this strategy is most effective for kinase-substrate
complexes of relatively high binding affinity and abundance.
A technique that allows the identification of the physio-
logical substrates of a kinase in vivo and with no bias for
affinity or abundance is needed.
In a previous study from the laboratories of Kevan Shokat
and David Morgan, Ubersax et al. [12] reported a screen
using chemical biology to identify substrates of Cdk1, a
master cell-cycle regulator. The authors designed a modified
Cdk1 (Cdk1-as, analog sensitive) with an enlarged ATP-
binding site, capable of accommodating and using a bulkier
radiolabeled ATP analog in phosphorylation reactions. The
ATP analog was designed to be unable to bind any cellular,
unmodified kinases. Because the ATP analog was cell-imper-
meable, however, Ubersax et al. [12] could not assay for
Cdk1 substrates in vivo and instead carried out the reactions
in cell extracts (as close to in vivo as possible). The reactions
combined recombinant cyclin B-Cdk1-as and multiple cell
extracts from yeast strains overexpressing single epitope-
tagged candidate substrates that were then purified and
assayed for their level of radioisotope incorporation. The
study tested a selected group of candidate proteins chosen
for their known involvement in the cell cycle and for the
presence of Cdk1 phosphorylation motifs, as well as a
random group. The result was the identification of some 200
potential substrates, and constitutes a milestone in cell-cycle
research. However, their strategy fell short of directly
identifying in vivo substrates.
A A   n ne ew w   s st tr ra at te eg gy y   t th ha at t   g go oe es s   i in n   v vi iv vo o
Now, they have done it. The same groups now report a
strategy [1] that allows the systematic identification of in
vivo kinase substrates. Again, the trick is to combine elements
of chemical biology and substrate prediction using bio-
informatics. As in the previous work, Snead et al. [1] began
by generating a modified but functional Cdc5 (Polo) kinase
with an enlarged binding site (L158G-substituted) capable of
accepting a cell-permeable inhibitor that has a low affinity
for the unmodified, wild-type Cdc5 (Figure 1a) and is not
predicted to be accommodated in the binding sites of any
other kinases of the genome. The resulting kinase, Cdc5-as1,
is still named ‘as’ for ‘analog-sensitive’ [13]. This general
approach has been used previously to selectively inhibit
several kinases [14]. However, the particularities of the Cdc5
ATP-binding site make it resistant to the usual pyrazolo-
pyrimidine (PP1) analog inhibitors and forced the use of a
pyrrolopyrimidine inhibitor containing a chloromethyl-
ketone (referred to as CMK).
With the new kinase-inhibitor pair in hand, Snead et al. [1]
constructed a strain of yeast in which the endogenous CDC5
gene was replaced with cdc5-as1 at the natural locus,
enabling the in vivo inhibition of Cdc5-as1, the only source
of Cdc5 in the cell. This was achieved without any significant
risk of simultaneously inhibiting other cellular kinases,
which is usually a problem when working with inhibitors
developed to target natural kinases.
Treatment of cdc5-as1 cells with CMK led to inhibition of
proliferation (Figure 1b). Cytological examination revealed
that cells arrested at or after anaphase. This on its own was
not surprising, as Cdc5 is known to be required for exit from
mitosis and cytokinesis [15]. But on close examination, an
increased percentage of cells had an elongated spindle that
was completely enclosed in the mother cell, instead of
normally spanning both the mother cell and the bud
(although this defect was eventually corrected). Moreover,
the early, short spindle was often misaligned and micro-
tubules were often misoriented or sometimes detached from
the spindle pole bodies (SPBs). Therefore, Cdc5 is required
for normal positioning and function of the mitotic spindle.
Inhibition of Cdc5 also led to premature sister-chromatid
separation, as expected. Altogether, these experiments revealed
both known and new roles for Cdc5 in the cell cycle. This
novel role for Cdc5 at the spindle level was not identified in
previous studies using temperature-sensitive (ts) alleles of
CDC5: this may be because such alleles often retain some
activity even at the restrictive temperature or because the
increase in temperature required to inactivate a ts allele can
alter cell-cycle progression.
Snead et al. [1] then set out to screen for substrates of Cdc5 in
silico and  in vivo. Using a sequence-profile-scanning
algorithm [16,17], they searched all yeast predicted proteins
(over 6,000 proteins) for Plk phosphorylation motifs and for
PBD-binding motifs (defined using published information
available for human and yeast Plks). As an output, each
protein was assigned a ‘Cdc5 substrate likelihood score’. From
among the highest-scoring proteins, functional criteria (for
example, known involvement in mitosis or cell cycle) were
used to choose a list of 192 candidates to be tested (Figure 1c).
The experimental part of the screen made use of a library of
strains in which genes are fused at their natural loci with a
tag that can be used for tandem affinity purification (TAP),
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proteins were then assayed for their phosphorylation state as
detected by a shift in electrophoretic mobility. A first screen
retained only those proteins from the candidate list that
changed in mobility (shifted) between G1 (Cdc5 inactive)
and mitosis (Cdc5 and other kinases active) (Figure 1d). Hits
from that stage (74) were finally assayed for a shift that was
dependent on treatment with CMK in mitotically arrested
cdc5-as1 cells (Figure 1e). Only five proteins passed this final
selection step; two of them are known Cdc5 substrates, while
three are novel. One of the novel substrates is Spc72, a SPB
component with known roles in microtubule nucleation and
spindle positioning [18-21]. Since it was known to interact
with Cdc5 [22,23], Spc72 was an obvious candidate for a
molecular target of Cdc5 in the regulation of the mitotic
spindle. Moreover, Cdc5 is known to localize to the SPB.
Snead et al. [1] showed that Cdc5 requires its PBD to interact
with Spc72 and can phosphorylate Spc72 in vitro. Finally,
they also assayed the binding of recombinant Cdc5 to a set of
90 TAP-tagged proteins annotated (or reported) as SPB-
localized in databases. Several of these proteins associated
with Cdc5, and Spc72 was among the most efficient inter-
actors, further suggesting a direct interaction.
A A   s si ig gn ni if fi ic ca an nt t   n ne ew w   a ad dv va an nc ce e
Further experiments will be required to clarify how Cdc5
regulates Spc72 and how this affects SPB and spindle function.
It is likely that disruption of the Cdc5-Spc72 pathway is at
least partly responsible for the cellular phenotypes obtained
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F Fi ig gu ur re e   1 1
Strategy used by Snead et al. [1] to identify substrates of yeast Polo-like kinase (Cdc5). ( (a a) ) A modified Cdc5 (Cdc5-as1) is generated to be selectively
inhibited by a small-molecule inhibitor (CMK) that does not affect wild-type Cdc5. K, kinase domain; PBD, Polo-box domain. ( (b b) ) Treatment of cdc5∆
cdc5-as1 cells with CMK reveals the cellular phenotypes associated with Cdc5 inhibition. ( (c c) ) A sequence-scanning algorithm identifies proteins containing
potential Plk phosphorylation motifs (blue), potential PBD-binding motifs (red) and satisfying functional criteria in database annotations (yellow). ( (d d) )
Individual strains expressing candidate substrates (P1, P2, P3, and so on) from their normal loci in fusion with the TAP tag are screened for
electrophoretic mobility shifts of the fusion protein between a G1 arrest (Cdc5 inactive) and an M-phase arrest (Cdc5 and other kinases active). ( (e e) ) For
fusion proteins showing a shift between G1 and M, strains combining the TAP-tagged gene with the cdc5∆ cdc5-as1 allele are generated. Those are then
screened for a CMK-dependent (Cdc5-dependent) mobility shift in M-phase-arrested cells. Hits from that final step can be considered to be physiological
Cdc5 substrates. The cellular phenotypes observed following Cdc5 inhibition in (b) may be hypothesized to result from a failure of phosphorylation of
one or more of the Cdc5 substrates identified.
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criteriawhen Cdc5 is inhibited in vivo. In animal cells, Plk1 is known
to promote centrosome maturation and microtubule
nucleation activity by various mechanisms [4,24]. Despite
marked differences between budding yeasts and animal cells
in how the spindle is assembled and regulated, it is
becoming clear in the light of the paper by Snead et al. that
the yeast Polo-like kinase Cdc5 is a major regulator of the
mitotic spindle.
Because many phosphoproteins do not produce a marked
shift in electrophoretic mobility when phosphorylated at a
given site, several Cdc5 substrates are likely to have been
missed in this screen. This may be even more problematic
for Cdc5 substrates that are also phosphorylated by other
mitotic kinases. Nonetheless, the experimental approach
presented by Snead et al. provides a powerful means of
systematically identifying physiological substrates of a
kinase in its natural environment - without overexpressing
the kinase or the candidate substrates to be screened. This
platform should be readily amenable to similar screens for
substrates of any kinase of choice in S. cerevisiae and
therefore constitutes a powerful handle on many signaling
pathways in cell biology. The technique is not yet easily
transferable to other organisms where exact gene replace-
ment and genomic tagging at the natural loci are, at present,
impracticable or challenging, including Drosophila,
Caenorhabditis elegans or mammalian cells. Nonetheless, a
recent paper reported the use of a Plk1-as allele (and a
specific inhibitor) to analyze Plk1 functions in cytokinesis in
human cells where endogenous Plk1 has been knocked out
by homologous recombination [25]. The viral expression of
Plk1-as in these experiments may not, however, follow the
normal levels or cell-cycle profile of endogenous Plk1
expression. In mammalian cells a screen for substrates such
as the one presented by Snead et al. would almost certainly
require the tagged candidates to be artificially expressed.
Again, the little budding yeast is first to stick its neck out and
one has to hope that technological advances will soon allow
other organisms to follow its path.
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